KOSDAQ - Delayed Quote KRW

OliX Pharmaceuticals, Inc (226950.KQ)

54,300.00
+4,200.00
+(8.38%)
At close: May 30 at 3:30:18 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
5,885,314.99
5,677,151.91
17,064,275.44
9,320,323.64
3,674,356.76
Gross Profit
5,885,314.99
5,677,151.91
17,064,275.44
9,320,323.64
3,674,356.76
Operating Expense
--
36,595,746
35,249,618
31,695,932
27,902,915
Operating Income
-19,849,088.01
-30,918,594.09
-18,185,342.56
-22,375,608.36
-24,228,558.24
Net Non Operating Interest Income Expense
-9,145,463.32
-4,227,445.34
-1,802,538.30
-1,541,831.10
-1,957,005.49
Pretax Income
-45,461,831.37
-41,070,667.60
-18,169,623.85
-29,107,615.45
-29,997,295.74
Tax Provision
--
-411,968
932,072.26
-994,902.92
-821,537.73
Net Income Common Stockholders
-45,518,786.58
-40,658,699.59
-19,101,696.12
-19,495,352.38
-29,714,663.86
Basic EPS
-2.67k
--
-1.32k
-1.42k
-2.17k
Diluted EPS
-2.67k
--
-1.32k
-1.42k
-2.17k
Basic Average Shares
18,459.57
--
14,427.26
13,700.18
13,706.03
Diluted Average Shares
18,459.57
--
14,427.26
13,700.18
13,706.03
Total Operating Income as Reported
-29,068,231.24
-30,918,594.16
-18,185,342.17
-22,375,609.57
-24,228,556.81
Rent Expense Supplemental
--
375,531
252,183
370,474
293,492
Total Expenses
--
36,595,746
35,249,618
31,695,932
27,902,915
Net Income from Continuing & Discontinued Operation
-45,518,786.58
-40,658,699.59
-19,101,696.12
-19,495,352.38
-29,714,663.86
Normalized Income
-45,995,724.58
-43,189,307.59
-21,059,437.12
-20,748,618.46
-24,287,989.20
Interest Income
--
433,806
1,267,621
1,388,468
473,687
Interest Expense
--
4,661,251
3,491,742
2,930,301
2,430,692
Net Interest Income
-9,145,463.32
-4,227,445.34
-1,802,538.30
-1,541,831.10
-1,957,005.49
EBIT
-27,378,373.37
-36,409,416.60
-14,677,881.85
-26,177,314.45
-27,566,603.74
EBITDA
-27,378,373.37
-33,783,237.25
-12,035,934.74
-24,102,778.72
-25,936,886.04
Reconciled Depreciation
--
2,626,179.35
2,641,947.11
2,074,535.73
1,629,717.70
Net Income from Continuing Operation Net Minority Interest
-45,518,786.58
-40,658,699.59
-19,101,696.12
-25,720,259.15
-28,612,521.03
Total Unusual Items Excluding Goodwill
476,938
2,556,249
2,575,975
-5,147,586
-4,446,303
Total Unusual Items
476,938
2,556,249
2,575,975
-5,147,586
-4,446,303
Normalized EBITDA
-27,855,311.37
-36,339,486.25
-14,611,909.74
-18,955,192.72
-21,490,583.04
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
25,641
618,234
-175,945.31
-121,771.17
12/31/2021 - 7/18/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

002630.KS ORIENT BIO Inc.
1,179.00
-8.46%
 
115180.KQ Qurient Co., Ltd.
10,620.00
-2.84%
 
475960.KQ TOMOCUBE
25,500.00
-4.32%
 
347850.KQ D&D Pharmatech
86,500.00
+1.76%
 
127120.KQ JS Link, Inc.
8,640.00
-0.46%
 
310210.KQ Voronoi, Inc.
105,700.00
-1.21%
 
087010.KQ Peptron, Inc.
232,500.00
+3.33%
 
950160.KQ Kolon TissueGene, Inc.
40,600.00
0.00%
 
298380.KQ ABL Bio Inc.
80,600.00
+3.60%
 
4592.T SanBio Company Limited
3,015.00
-11.71%